<p>安富利製藥公司（NASDAQ:AMPH - 獲取免費報告）董事 Floyd Petersen 於 12 月 11 日星期四出售了 1,737 股該公司的股票。股票以平均價格 25.69 美元出售，總交易額為 44,623.53 美元。交易完成後，該董事直接持有 73,794 股公司股票，估值約為 1,895,767.86 美元。此次交易使其持股比例減少了 2.30%。該出售在向 SEC 的法律文件中披露，相關信息可通過 SEC 網站訪問。</p>
<h2>安富利製藥股價上漲 4.1%</h2>
<ul>
<li>在降息前值得購買的前兩隻小型醫療股</li>
</ul>
<p>在週一的午盤交易中，NASDAQ:AMPH 的股價上漲了 1.04 美元，達到了 26.31 美元。該公司的交易量為 472,889 股，而其平均交易量為 527,280 股。該公司的流動比率為 3.12，速動比率為 2.21，債務與股本比率為 0.78。安富利製藥公司過去 12 個月的最低股價為 20.39 美元，最高股價為 42.49 美元。該公司的 50 日簡單移動平均線為 25.52 美元，200 日簡單移動平均線為 25.66 美元。該股票的市值為 12.1 億美元，市盈率為 11.64，PEG 比率為 7.08，貝塔值為 0.91。</p>
<p>安富利製藥（NASDAQ:AMPH - 獲取免費報告）最近於 11 月 6 日星期四發佈了其財報。該公司報告本季度每股收益為 0.93 美元，超出市場共識預期的 0.83 美元，超出 0.10 美元。該公司本季度的收入為 1.9184 億美元，而分析師預期為 1.8690 億美元。安富利製藥的股本回報率為 19.70%，淨利潤率為 15.43%。分析師平均預測安富利製藥公司本年度每股收益為 3.49 美元。</p>
<h2>分析師評級上調與下調</h2>
<ul>
<li>前景看好的小型生物科技公司安富利製藥出現可操作的回調</li>
</ul>
<p>幾家研究公司對 AMPH 進行了評估。巴克萊在 12 月 9 日星期二發佈的報告中對安富利製藥的股票進行了覆蓋，給予 “持平” 評級，目標價為 30.00 美元。Needham &amp; Company LLC 在 11 月 7 日星期五的研究報告中將安富利製藥的目標價從 36.00 美元下調至 34.00 美元，並給予該股票 “買入” 評級。Weiss Ratings 在 12 月 8 日星期一的報告中重申了對安富利製藥股票的 “持有（c）” 評級。美國銀行在 8 月 26 日星期二的研究報告中將安富利製藥的目標價從 28.00 美元上調至 32.00 美元，並給予該股票 “中性” 評級。最後，Zacks Research 在 11 月 14 日星期五的研究報告中將安富利製藥的評級從 “強力買入” 下調至 “持有”。兩位研究分析師對該股票給予 “買入” 評級，六位分析師給予該公司 “持有” 評級。根據 MarketBeat 的數據，安富利製藥的共識評級為 “持有”，平均目標價為 31.00 美元。</p>
<p><strong>獲取我們對安富利製藥的最新分析</strong></p>
<h2>機構資金流入與流出</h2>
<p>一些對沖基金最近增加或減少了對 AMPH 的持股。FNY 投資顧問公司在第三季度收購了安富利製藥的新股份，價值約為 26,000 美元。丹麥銀行在第三季度購買了安富利製藥的新股份，價值約為 614,000 美元。Quarry LP 在第三季度購買了安富利製藥的新股份，價值約為 32,000 美元。Millennium Management LLC 在第三季度將其在安富利製藥的持股增加了 12.7%。Millennium Management LLC 現在擁有 697,765 股該公司的股票，價值為 18,595,000 美元，此前在上個季度購買了額外的 78,781 股。最後，Lighthouse Investment Partners LLC 在第三季度以約 576,000 美元的價格購買了安富利製藥的新股份。機構投資者持有該公司 65.09% 的股票。</p>
<h2>安富利製藥公司簡介</h2>
<p>（獲取免費報告）</p>
<p>安富利製藥公司是一家生物製藥公司，在美國、中國和法國開發、生產、營銷和銷售仿製藥和專有的注射劑、吸入劑和鼻用產品。它提供 BAQSIMI，一種用於治療嚴重低血糖的鼻用噴霧劑；Primatene Mist，一種用於暫時緩解間歇性哮喘輕微症狀的非處方腎上腺素吸入產品；恩諾沙班，用於預防和治療深靜脈血栓；REXTOVY 和納洛酮用於阿片類藥物過量；用於注射的急救用胰高血糖素；以及 Cortrosyn，用作篩查腎上腺皮質功能不全患者的診斷劑。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票超過安富利製藥</li>
<li>如何計算投資回報率（ROI）</li>
<li>ServiceNow 的 70 億美元賭注：恐慌還是機會？</li>
<li>關注國會股票交易</li>
<li>戴爾和惠普正在漲價——投資者應注意</li>
<li>投資者最重要的沃倫·巴菲特股票：他自己的股票</li>
<li>為什麼 DLocal 是 2026 年值得關注的頂級新興市場金融科技股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在安富利製藥嗎？</h2>
<p>在考慮安富利製藥之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Amphastar Pharmaceuticals 並不在名單上。</p>
<p>雖然 Amphastar Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Amphastar制藥

<p>Amphastar 製藥董事 Floyd Petersen 出售了 1,737 股，獲得 44,623.53 美元，減少了 2.30% 的持股比例。此次出售在 SEC 文件中披露。Amphastar 的股票上漲了 4.1%，達到 26.31 美元，市值為 12.1 億美元。分析師的評級不一，普遍持有 “持有” 評級，平均目標價為 31.00 美元。機構投資者持有 65.09% 的股份</p>

<p>Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) Director Floyd Petersen sold 1,737 shares of the firm's stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $25.69, for a total transaction of $44,623.53. Following the completion of the transaction, the director directly owned 73,794 shares in the company, valued at approximately $1,895,767.86. The trade was a 2.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.</p>
<div class="lb-trans"><p>安富利製藥公司（NASDAQ:AMPH - 獲取免費報告）董事 Floyd Petersen 於 12 月 11 日星期四出售了 1,737 股該公司的股票。股票以平均價格 25.69 美元出售，總交易額為 44,623.53 美元。交易完成後，該董事直接持有 73,794 股公司股票，估值約為 1,895,767.86 美元。此次交易使其持股比例減少了 2.30%。該出售在向 SEC 的法律文件中披露，相關信息可通過 SEC 網站訪問。</p>
</div><h2>Amphastar Pharmaceuticals Trading Up 4.1%</h2>
<div class="lb-trans"><h2>安富利製藥股價上漲 4.1%</h2>
</div><ul>
<li>Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts</li>
</ul>
<div class="lb-trans"><ul>
<li>在降息前值得購買的前兩隻小型醫療股</li>
</ul>
</div><p>Shares of NASDAQ:AMPH traded up $1.04 during midday trading on Monday, hitting $26.31. The company had a trading volume of 472,889 shares, compared to its average volume of 527,280. The company has a current ratio of 3.12, a quick ratio of 2.21 and a debt-to-equity ratio of 0.78. Amphastar Pharmaceuticals, Inc. has a 12 month low of $20.39 and a 12 month high of $42.49. The firm has a fifty day simple moving average of $25.52 and a 200 day simple moving average of $25.66. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of 11.64, a PEG ratio of 7.08 and a beta of 0.91.</p>
<div class="lb-trans"><p>在週一的午盤交易中，NASDAQ:AMPH 的股價上漲了 1.04 美元，達到了 26.31 美元。該公司的交易量為 472,889 股，而其平均交易量為 527,280 股。該公司的流動比率為 3.12，速動比率為 2.21，債務與股本比率為 0.78。安富利製藥公司過去 12 個月的最低股價為 20.39 美元，最高股價為 42.49 美元。該公司的 50 日簡單移動平均線為 25.52 美元，200 日簡單移動平均線為 25.66 美元。該股票的市值為 12.1 億美元，市盈率為 11.64，PEG 比率為 7.08，貝塔值為 0.91。</p>
</div><p>Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.10. The firm had revenue of $191.84 million for the quarter, compared to analyst estimates of $186.90 million. Amphastar Pharmaceuticals had a return on equity of 19.70% and a net margin of 15.43%. On average, analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.49 EPS for the current year.</p>
<div class="lb-trans"><p>安富利製藥（NASDAQ:AMPH - 獲取免費報告）最近於 11 月 6 日星期四發佈了其財報。該公司報告本季度每股收益為 0.93 美元，超出市場共識預期的 0.83 美元，超出 0.10 美元。該公司本季度的收入為 1.9184 億美元，而分析師預期為 1.8690 億美元。安富利製藥的股本回報率為 19.70%，淨利潤率為 15.43%。分析師平均預測安富利製藥公司本年度每股收益為 3.49 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><ul>
<li>Promising Small Biotech Amphastar Sees Actionable Pullback</li>
</ul>
<div class="lb-trans"><ul>
<li>前景看好的小型生物科技公司安富利製藥出現可操作的回調</li>
</ul>
</div><p>Several research firms have weighed in on AMPH. Barclays initiated coverage on shares of Amphastar Pharmaceuticals in a report on Tuesday, December 9th. They issued an &#34;equal weight&#34; rating and a $30.00 target price on the stock. Needham &amp; Company LLC dropped their price target on Amphastar Pharmaceuticals from $36.00 to $34.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, November 7th. Weiss Ratings reiterated a &#34;hold (c)&#34; rating on shares of Amphastar Pharmaceuticals in a report on Monday, December 8th. Bank of America increased their target price on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a &#34;neutral&#34; rating in a research note on Tuesday, August 26th. Finally, Zacks Research lowered shares of Amphastar Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Friday, November 14th. Two research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Amphastar Pharmaceuticals has a consensus rating of &#34;Hold&#34; and an average price target of $31.00.</p>
<div class="lb-trans"><p>幾家研究公司對 AMPH 進行了評估。巴克萊在 12 月 9 日星期二發佈的報告中對安富利製藥的股票進行了覆蓋，給予 “持平” 評級，目標價為 30.00 美元。Needham &amp; Company LLC 在 11 月 7 日星期五的研究報告中將安富利製藥的目標價從 36.00 美元下調至 34.00 美元，並給予該股票 “買入” 評級。Weiss Ratings 在 12 月 8 日星期一的報告中重申了對安富利製藥股票的 “持有（c）” 評級。美國銀行在 8 月 26 日星期二的研究報告中將安富利製藥的目標價從 28.00 美元上調至 32.00 美元，並給予該股票 “中性” 評級。最後，Zacks Research 在 11 月 14 日星期五的研究報告中將安富利製藥的評級從 “強力買入” 下調至 “持有”。兩位研究分析師對該股票給予 “買入” 評級，六位分析師給予該公司 “持有” 評級。根據 MarketBeat 的數據，安富利製藥的共識評級為 “持有”，平均目標價為 31.00 美元。</p>
</div><p><strong>Get Our Latest Analysis on Amphastar Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>獲取我們對安富利製藥的最新分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入與流出</h2>
</div><p>A number of hedge funds have recently added to or reduced their stakes in AMPH. FNY Investment Advisers LLC acquired a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter worth about $26,000. Danske Bank A S bought a new stake in Amphastar Pharmaceuticals during the third quarter worth about $614,000. Quarry LP bought a new stake in Amphastar Pharmaceuticals during the third quarter worth about $32,000. Millennium Management LLC boosted its position in Amphastar Pharmaceuticals by 12.7% during the third quarter. Millennium Management LLC now owns 697,765 shares of the company's stock valued at $18,595,000 after purchasing an additional 78,781 shares during the last quarter. Finally, Lighthouse Investment Partners LLC bought a new position in Amphastar Pharmaceuticals in the third quarter valued at approximately $576,000. Institutional investors own 65.09% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金最近增加或減少了對 AMPH 的持股。FNY 投資顧問公司在第三季度收購了安富利製藥的新股份，價值約為 26,000 美元。丹麥銀行在第三季度購買了安富利製藥的新股份，價值約為 614,000 美元。Quarry LP 在第三季度購買了安富利製藥的新股份，價值約為 32,000 美元。Millennium Management LLC 在第三季度將其在安富利製藥的持股增加了 12.7%。Millennium Management LLC 現在擁有 697,765 股該公司的股票，價值為 18,595,000 美元，此前在上個季度購買了額外的 78,781 股。最後，Lighthouse Investment Partners LLC 在第三季度以約 576,000 美元的價格購買了安富利製藥的新股份。機構投資者持有該公司 65.09% 的股票。</p>
</div><h2>Amphastar Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>安富利製藥公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.</p>
<div class="lb-trans"><p>安富利製藥公司是一家生物製藥公司，在美國、中國和法國開發、生產、營銷和銷售仿製藥和專有的注射劑、吸入劑和鼻用產品。它提供 BAQSIMI，一種用於治療嚴重低血糖的鼻用噴霧劑；Primatene Mist，一種用於暫時緩解間歇性哮喘輕微症狀的非處方腎上腺素吸入產品；恩諾沙班，用於預防和治療深靜脈血栓；REXTOVY 和納洛酮用於阿片類藥物過量；用於注射的急救用胰高血糖素；以及 Cortrosyn，用作篩查腎上腺皮質功能不全患者的診斷劑。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Amphastar Pharmaceuticals</li>
<li>How to Calculate Return on Investment (ROI)</li>
<li>ServiceNow’s $7 Billion Gamble: Panic or Opportunity?</li>
<li>Following Congress Stock Trades</li>
<li>Dell and HP Are Raising Prices—And Investors Should Take Note</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>Why DLocal Is the Top Emerging Market Fintech Stock to Watch for 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過安富利製藥</li>
<li>如何計算投資回報率（ROI）</li>
<li>ServiceNow 的 70 億美元賭注：恐慌還是機會？</li>
<li>關注國會股票交易</li>
<li>戴爾和惠普正在漲價——投資者應注意</li>
<li>投資者最重要的沃倫·巴菲特股票：他自己的股票</li>
<li>為什麼 DLocal 是 2026 年值得關注的頂級新興市場金融科技股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=AMPH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amphastar Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在安富利製藥嗎？</h2>
</div><p>Before you consider Amphastar Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮安富利製藥之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Amphastar Pharmaceuticals 並不在名單上。</p>
</div><p>While Amphastar Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Amphastar Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Amphastar 製藥（NASDAQ:AMPH）的一位董事出售了價值 44,623.53 美元的股票